Form 4: TransMedics Group Director James Tobin Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
Director James Tobin sold shares of TransMedics Group, Inc. on May 3, 2024, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On May 3, 2024, James R. Tobin, a director of TransMedics Group, Inc., sold shares of common stock.
- The sales were executed under a Rule 10b5-1 trading plan established on November 21, 2023.
- Tobin sold 5,130 shares at a weighted average price of $124.76, with prices ranging from $124.75 to $124.94.
- An additional 6,895 shares were sold at a weighted average price of $125.26, with prices ranging from $125.00 to $125.80.
- Following these transactions, Tobin directly owns 1,193 shares and indirectly owns 393,187 shares through the James R. Tobin 2012 Trust.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing related to insider trading. The sales were conducted under a pre-arranged plan, so it's neutral from an investment perspective.
Industry Context
Sales by company directors are a normal part of corporate governance. The fact that these sales were executed under a pre-arranged 10b5-1 trading plan suggests that the sales were planned and not based on any inside information.
Stakeholder Impact
- The share sales may have a minor impact on shareholder sentiment, but the pre-planned nature of the transactions mitigates potential concerns.
Key Dates
| Date | Description |
|---|---|
| 2023-11-21 | Date of Rule 10b5-1 trading plan adoption. |
| 2024-05-03 | Date of share sale transactions. |
| 2024-05-07 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.